Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: A case series study

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 1, 2012, Pages 10-16

  Vitale, Felice Vito ^a   Rotondo, Stefano ^b   Sessa, Edoardo ^b   Parisi, Alessandra ^a   Giaimo, Valentina ^a   D'Angelo, Alessandro ^a   Antonelli, Giovanna ^a   Romeo, Placido ^a   Ferraù, Francesco ^a  

^a San Vincenzo Hospital   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

brain metastases; cancer; intracranial hemorrhage; Low molecular weight heparin; thromboembolism

Indexed keywords

ENOXAPARIN; NADROPARIN; PARNAPARIN; REVIPARIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCOAGULABILITY; INTRACARDIAC THROMBOSIS; LUNG EMBOLISM; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SUPERFICIAL THROMBOPHLEBITIS; TREATMENT DURATION;

ADULT; AGED; ANTICOAGULANTS; BRAIN NEOPLASMS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; TIME FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84857988670     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210390254     Document Type: Article

References (39)

1. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996 ; 10: 499-530 (Pubitemid 26097349)
2. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer. Acta Haematol. 2001 ; 106: 33-42
3. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007 ; 13: 2870-2875 (Pubitemid 46849560)
4. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 ; 166: 458-464
5. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003 ; 107: I17 - I21
6. Wen PY, Loeffler JS. Management of brain metastases. Oncology. 1999 ; 13: 941-961
7. Westphal M, Heese O, and de Wit M. Intracranial metastases:therapeutic options. Ann Oncol. 2003 ; 14: iii4 - iii10
8. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001 ; 106: 6-12 (Pubitemid 32830510)
9. Kondziolka D, Bernstein M, Resch L, Tator CH, Ross Fleming JF, Venderlinden RG, et al. Significance of hemorrhage into brain tumors: clinicopathologic study. J Neurosurg. 1987 ; 67: 852-857 (Pubitemid 18005530)
10. Salmaggi A, Erbetta A, Silvani A, Maderna E, Pollo B. Intracerebral haemorrhage in primary and metastatic brain tumours. Neurol Sci. 2008 ; 29: S264 - S265
11. Schiff D, De Angelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994 ; 73: 493-498 (Pubitemid 24030634)
12. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PMCL, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993 ; 43: 1111-1114 (Pubitemid 23177708)
13. Rogers LR. Cerebrovascular complications in cancer patients. Neurol Clin. 2003 ; 21: 167-192 (Pubitemid 36172467)
14. Carden CP, Larkin JMG, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol. 2008 ; 10: 624-630
15. Izawa M, Chernov M, Hayashi M, Kubota Y, Kasuya H, Hori T. Fatal intratumoral hemorrhage immediately after gamma knife radiosurgery for brain metastases: case report. Minim Invasive Neurosurg. 2006 ; 49: 251-254 (Pubitemid 44606709)
16. Anderson WS, Moore LE, Ford E, Rigamonti D. Fatal case of intracerebral hemorrhage during gamma knife treatment for metastases. Clin Neurol Neurosurg. 2008 ; 110: 838-842
17. Natal F. Radiosurgery for brain metastases. Neurochirurgie. 1999 ; 45: 393-397
18. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. 2006 ; 24: 1310-1318 (Pubitemid 46622035)
19. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bevin EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors: anticoagulants or inferior vena cava filters?. Arch Intern Med. 1987 ; 147: 2177-2179 (Pubitemid 18008723)
20. Norris LK, Grossman SA. Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol. 1994 ; 22: 127-137
21. Monreal M, Zacharsky L, Jimenez JA, Roncales J, Vilaseca B. Fixed-dose low-molecular weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost. 2004 ; 2: 1311-1315 (Pubitemid 40186126)
22. Vitale FV, Rotondo S, Sessa E, Antonelli G, Colina P, Parisi A, et al. Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases. J Oncol Pharm Pract. :
23. Farge D, Durant C, Villiers S, Long A, Mahr A, Marty M, et al. Lessons from French national guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res. 2010 ; 125: S108 - S116
24. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 ; 25: 5490-5505 (Pubitemid 350232226)
25. Venous thromboembolic disease NCCN guidelines V1. 2010. Online Referencing, http://www.nccn.org/professionals/gls/fguidelines.asp (2010, accessed Sept. 24, 2010).
26. Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, et al. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol. 2010 ; 73: 31-46
27. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 ; 133: 454S - 545S (Pubitemid 351892971)
28. Mandalà M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol. 2006 ; 59: 194-204 (Pubitemid 44403960)
29. Mandalà M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol. 2008 ; 19: iii126 - iii127
30. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Bagatella P, Sabbion P, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 ; 100: 3484-3488 (Pubitemid 35303914)
31. Bauer KA. Venous thromboembolism in malignancy. J Clin Oncol. 2000 ; 18: 3065-3067
32. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000 ; 18: 3078-3083
33. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002 ; 162: 1729-1735
34. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 ; 349: 146-153
35. Lee AYY. Treatment and secondary prophylaxis of VTE in the cancer patient: current status. Pathophysiol Haemost Thromb. 2003 ; 33: 42-43 (Pubitemid 37490528)
36. Lee AYY. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. Thromb Res. 2007 ; 120: S121 - S127
37. Levine MN, Lee AYY. Treatment of venous thrombosis in the cancer patient. Acta Haematol. 2001 ; 106: 81-87 (Pubitemid 32830520)
38. Magagnoli M, Masci G, Castagna L, Morenghi E, Santoro A. High incidence of INR alteration in gastrointestinal cancer patients treated with mini dose warfarin and 5-fluorouracil-based regimens. Ann Oncol. 2006 ; 17: 174-176 (Pubitemid 43033860)
39. Haas SS, Schellong S. New anticoagulants: from bench to bedside. Hämostaseologie. 2007 ; 27: 41-47 (Pubitemid 46280048)